ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE

NCT ID: NCT03296150

Last Updated: 2024-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

139 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-29

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes. Poor adherence affects particularly geriatric patients due among others to polypharmacy or cognitive impairment. Thus, the need for educational programs in this population has been regularly emphasized.

PRESTAGE educational program was built after an external and internal analysis of educational needs in elderly patients treated with oral cancer treatments. It implicates a multidisciplinary educational team (nurses, physicians, pharmacists, psychologists, physiologists, social workers...). Six educational workshops were designed with the following endpoints: disease and treatment understanding, treatment management, nutrition and psychological as well as physical well being.

ADOPT-PRESTAGE is a clinical, prospective, interventional, open-label, multicenter, randomized, controlled trial designed to evaluate the impact of PRESTAGE program. It is, to the investigators' knowledge, the first randomized controlled trial evaluating the acceptability and impact (adherence, clinical benefit) of an educational program in an elderly cancer population. The primary endpoint of this trial will be to evaluate adherence using an indirect objective adherence measure: the Medication Event Monitoring System (MEMS). Secondary endpoints include quality of life and evaluation of changes in patients' behaviors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Oral Anticancer Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control arm : Information

Patients will receive the usual standard information delivered to patients

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention arm : Therapeutic educational program

Patients will receive the therapeutic educational program "PRESTAGE"

Group Type EXPERIMENTAL

PRESTAGE

Intervention Type BEHAVIORAL

PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRESTAGE

PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 70 years,
* For which oral anticancer therapy has been initiated within the previous 45 days or will be started within 45 days
* For any type of cancer, solid or hematologic, any stage
* Estimated life expectancy\> 6 months
* Affiliation to social security or equivalent
* Patients who can answer questionnaires and protocol evaluations
* Informed consent signed by patients
* Domiciled within 50 km around the investigating center

Exclusion Criteria

* For patients with breast cancer, exclusive treatment with hormone therapy
* First-generation Hormone Therapy in Prostate Cancer
* Patient not available for regular follow-up whatever the cause (geographic, family, social, psychological)
* Any serious condition, ie serious physical or mental, leading to a disability permanent and likely to prevent the proper course of treatment
* Patient deprived of liberty or under guardianship
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olivia LE SAUX

Role: STUDY_CHAIR

Hospices Civils de Lyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de neuro-oncologie, Hôpital Pierre Wertheimer, HCL

Bron, , France

Site Status RECRUITING

Service de Gériatrie, Centre Hospitalier de Givors

Givors, , France

Site Status WITHDRAWN

Service d'oncologie médicale, Centre Hospitalier Universitaire de Grenbole

La Tronche, , France

Site Status WITHDRAWN

Service de Médecine du vieillissement, Hôpital Edouard Herriot, HCL

Lyon, , France

Site Status RECRUITING

Service de médecine du vieillissement, Hôpital de la Croix-Rousse, HCL

Lyon, , France

Site Status RECRUITING

Service d'oncologie médicale, Cnetre Léon Bérard

Lyon, , France

Site Status NOT_YET_RECRUITING

Service d'oncologie, Centre Hospitalier Annecy Genevois

Metz-Tessy, , France

Site Status NOT_YET_RECRUITING

Service de Médecine du vieillissement, Centre Hospitalier Lyon Sud (Hospices Civils de Lyon)

Pierre-Bénite, , France

Site Status RECRUITING

service de gériatrie, Hôpital de la Charité, Centre Hospitalier Universitaire de St-Etienne

Saint-Etienne, , France

Site Status WITHDRAWN

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Olivia LE SAUX

Role: CONTACT

04 78 86 37 75 ext. +33

Claire FALANDRY, MD

Role: CONTACT

04 78 86 15 80 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

François DUCRAY, MD

Role: primary

Byeul-A KIM, MD

Role: primary

Amandine BRUYAS, MD

Role: primary

Olivier TREDAN, MD

Role: primary

Laëtitia STEFANI, MD

Role: primary

Olivia LE SAUX

Role: primary

Claire FALANDRY, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL16_0149

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.